Modulating the Tumour Microenvironment banner

Better understanding of the tumour microenvironment, and its influence on response to therapy, is key to developing the right strategies to target specific tumour antigens and kill the cancer cells. By studying the different cell types – T cell, myeloid cells, fibroblasts, NK cells, B cells, etc. -- and their roles in tumor initiation, progression, and resistance, companies can better predict response to therapy, and thereby design better immunotherapies to target solid and hematologic cancers.

Recommended Short Course*
Monday, 13 November, 14:00 – 17:00
SC3: The Tumour Microenvironment and Response to Cancer Immunotherapy
*Separate registration required. See short courses page for details. All short courses take place in-person only.






For more details on the conference, please contact:

Mimi Langley
Senior Conference Director
Cambridge Healthtech Institute
Phone: (+1) 781-972-5439
Email: mlangley@healthtech.com

 

For sponsorship information, please contact:

Companies A-K
Jason Gerardi
Sr. Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-972-5452
Email: jgerardi@healthtech.com

Companies L-Z
Ashley Parsons
Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-972-1340
Email: ashleyparsons@healthtech.com